Abemaciclib


Abemaciclib is a drug for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6.
It was designated as a breakthrough therapy for breast cancer by the U.S. Food and Drug Administration in October 2015.
On 28 September 2017, it was approved for use in the United States by the FDA for the treatment of certain breast cancers.

Medical uses

Since September 2017 Abemaciclib is approved in the US for "adult patients who have hormone receptor -positive, human epidermal growth factor receptor 2 -negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient's hormones".
In studies that compared fulvestrant plus abemaciclib to fulvestrant plus placebo in breast cancer patients, progression-free survival under abemaciclib therapy was 16.4 months on average, as compared to 9.3 months under the placebo regimen.

Side effects

Side effects that occurred in 20% or more of patients in studies were diarrhea, nausea and vomiting, leukopenia including neutropenia, anemia, thrombocytopenia, stomach pain, infections, fatigue, decreased appetite, and headache.

Interactions

As abemaciclib is mainly metabolized by the liver enzyme CYP3A4, inhibitors of this enzyme are expected to increase its blood plasma concentrations. Conversely, CYP3A4 inducers lower plasma concentrations of abemaciclib, as has been shown in a study with rifampicin.

Pharmacology

Mechanism of action

Like the related drugs palbociclib and ribociclib, abemaciclib inhibits the enzymes cyclin-dependent kinase 4 and cyclin-dependent kinase 6. These enzymes are responsible for phosphorylating and thus deactivating the retinoblastoma protein, which plays a role in cell cycle progression from the G1 to the S phase. Blocking this pathway prevents cells from progressing to the S phase, thereby inducing apoptosis.

Pharmacokinetics

After oral intake, absolute bioavailability is 45%. Highest blood plasma concentrations are reached after 8 hours on average. When in the circulation, 96.3% of abemaciclib is bound to plasma proteins. The substance is mainly metabolized by the liver enzyme CYP3A4 to N-desethylabemaciclib, and to a lesser extent to hydroxy derivatives and another oxidative metabolite. These metabolites have high plasma protein binding rates similar to the parent substance.
Abemaciclib is excreted mainly via the feces and to a small extent via the urine. Its elimination half-life is 18.3 hours on average.

Clinical trials

Successful Phase I and Phase II trials against breast cancer were announced in May and December 2014 respectively.
As of early 2016, abemaciclib was involved in 3 Phase III clinical trials:
Abemaciclib may be synthesized in a four step manner using a Suzuki coupling, followed by a Buchwald–Hartwig amination with the final step being a reductive amination using the Leuckart reaction.